etrasimod (Velsipity) is FDA approved. The FDA granted its approval on October 12, 2023. This approval allows for the use of etrasimod in the treatment of adults with moderately to severely active ulcerative colitis.

Aug 7th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Momelotinib, marketed under the brand name Ojjaara, was approved by the FDA on September 15, 2023.

Instil Bio and ImmuneOnco reveal partnership for IMM2510, a leading PD-L1xVEGF bispecific antibody, and IMM27M, an advanced anti-CTLA-4 antibody.

Motixafortide, marketed under the brand name Aphexda, was approved by the FDA on September 8, 2023.

Lilly's tirzepatide shows positive results in phase 3 trial for obese adults with heart failure and preserved ejection fraction.

Pozelimab, marketed under the brand name Veopoz, is FDA approved.

REGENXBIO Inc. announced fresh, encouraging interim results on safety and efficacy from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 in Duchenne muscular dystrophy patients aged 1 to 11 years.

Elranatamab, marketed under the brand name Elrexfio, is FDA approved. It received FDA approval for the treatment of adults with multiple myeloma.

Health Canada has authorized the use of Celltrion's Steqeyma®, a biosimilar of Stelara® (ustekinumab), for managing various persistent inflammatory diseases.

Talquetamab, marketed under the brand name Talvey, is FDA approved. It received approval for the treatment of adults with multiple myeloma.

Aug 6th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.